Everolimus and pazopanib (E/P) benefit genomically selected patients with metastatic urothelial carcinoma

BackgroundMetastatic urothelial carcinoma (mUC) is a genomically diverse disease with known alterations in the mTOR pathway and tyrosine kinases including FGFR. We investigated the efficacy and safety of combination treatment with everolimus and pazopanib (E/P) in genomically profiled patients with mUC.MethodsmUC patients enrolled on a Phase I dose escalation study and an expansion cohort treated with E/P were included. The primary end point …